Jessica J. Tao

Binghamton University

Full Professor(heuristic)

Cancer Genomics and Diagnostics · Cancer Research

h-index15

i10-index21

Publications107

Citations1,961

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 28

OGCT-02 A TRANSLATIONAL OBSERVATIONAL BIOREPOSITORY AND MANAGEMENT STUDY IN PATIENTS WITH BREAST CANCER LEPTOMENINGEAL METASTASIS: THE BIOLEPT STUDY
Neuro-Oncology Advances · 2025-08-01
Abstract P1-01-20: Spliceosome Mutations (Smut) in Metastatic Breast Cancer (MBC): An Analysis of a De-centralized Clinical Trial and Large Clinical-Genomic Dataset
Clinical Cancer Research · 2025-06-13
OnPOINT: Development of an open navigator through precision oncology informatics technology to support precision oncology decisions and genotype-matched clinical trial enrollment.
Journal of Clinical Oncology · 2025-05-28
NCMP-16. CNS METASTATIC PATTERNS IN BREAST CANCER TREATED WITH CDK4/6 INHIBITORS: PRELIMINARY RESULTS OF A RETROSPECTIVE ANALYSIS
Neuro-Oncology · 2024-11-01
Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion
JCO Precision Oncology · 2024-10-01 · 5 citations
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
Journal of Clinical Oncology · 2024-09-06 · 38 citations
Supplemental Table 3 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable TargetsPreprint
2024-09-03
Data from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable TargetsPreprint
2024-09-03
Supplemental Figure 3 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable TargetsPreprint
2024-09-03
Supplemental Figure 5 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable TargetsPreprint
2024-09-03
Supplemental Figure 4 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable TargetsPreprint
2024-09-03
Supplemental Table 1 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable TargetsPreprint
2024-09-03
Supplemental Figure 2 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable TargetsPreprint
2024-09-03
Supplemental Table 4 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable TargetsPreprint
2024-09-03
Supplemental Figure 5 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable TargetsPreprint
2024-09-03
Supplemental Figure 2 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable TargetsPreprint
2024-09-03
Supplemental Figure 3 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable TargetsPreprint
2024-09-03
Supplemental Figure 6 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable TargetsPreprint
2024-09-03
Data from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable TargetsPreprint
2024-09-03
Supplemental Figure 1 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable TargetsPreprint
2024-09-03

Open author page on OpenAlex →